Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Aug 13, 2026
James Hardie Industries (JHX) Stock Jumps +27% in 30 Days on Strong Earnings and Guidance Raise

James Hardie Industries (JHX) Stock Jumps +27% in 30 Days on Strong Earnings and Guidance Raise

Key Takeaways

  • JHX shares rose roughly 27% over the 30 days through mid-August, from a July 13 closing level near $24.29 to about $30.86.
  • The advance accelerated after James Hardie reported stronger-than-expected fiscal first-quarter 2027 results and raised its full-year sales and adjusted EBITDA guidance.
  • Fiber-cement Siding & Trim returned to 20% organic growth, while Deck, Rail & Accessories sell-through improved and international revenue grew at a double-digit pace.
  • Several analysts raised price targets, and the stock reached a 52-week high near $30.99 after a Barclays upgrade.
  • Over the trailing three months, JHX gained roughly 53%, reflecting the post-AZEK integration story and stronger execution despite a still-subdued U.S. housing backdrop.

James Hardie Industries (JHX) Company Overview and Market Position

James Hardie Industries plc is a leading manufacturer of fiber cement siding and building products, with North America accounting for the majority of its operating income. The company also operates in Australia, New Zealand, and Europe. Its product portfolio includes Hardie siding and trim, ColorPlus and Statement collections, and, following the AZEK acquisition, TimberTech decking and railing along with AZEK Exteriors.

Investors follow JHX for its exposure to U.S. residential construction and repair-and-remodel demand, its pricing power, and its long-running strategy of converting market share from vinyl and wood siding. The company is widely viewed as the dominant player in fiber cement, supported by brand strength, manufacturing scale, and distribution relationships. I also checked this using Tickeron’s AI Screener to see how JHX compares to others in the industry.

James Hardie Industries (JHX) Stock Price Performance: Last 30 Days vs. Quarter

In the 30 days through mid-August, JHX climbed from a closing price of $24.29 on July 13 to roughly $30.86 on August 12, a gain of about 27%. The move was not linear: shares traded mainly between roughly $24.80 and $26.50 during mid-to-late July, pulled back toward $24.78 on July 22, and then broke sharply higher after the August 6 earnings report. The stock rose about 8% on August 7 and touched a 52-week high near $30.99 on August 10.

Over the trailing three months, the move was even stronger. From a closing level near $20.19 on May 12, JHX advanced to about $30.86, a gain of roughly 53%. The quarterly trend shows a sustained recovery from the mid-May base, with higher lows through June and July and an August acceleration.

What Drove JHX Stock Price in the Last 30 Days

The main catalyst was the fiscal first-quarter 2027 earnings report released on August 6. James Hardie reported net sales of approximately $1.475 billion, up 64% on a reported basis and 12% on a pro forma basis, with adjusted EBITDA of about $422 million and an adjusted EBITDA margin of 28.6%. Adjusted earnings per share were $0.36, up 13% year over year.

Management raised fiscal 2027 sales guidance to $5.564 billion–$5.723 billion, up from $5.25 billion–$5.41 billion, and lifted adjusted EBITDA guidance to $1.536 billion–$1.625 billion. Fiber-cement Siding & Trim sales rose 34% to $859.8 million, including 20% organic growth, helped by ColorPlus, Statement Essentials, the Trim-Over installation method, and stronger higher-end repair-and-remodel demand. Deck, Rail & Accessories sales declined 5% to $305.1 million on planned channel-inventory normalization, but sell-through improved to near double-digit levels into July.

Sentiment was further supported by distribution expansion, including a national partnership with Boise Cascade and agreements with six regional distributors. Analyst actions reinforced the move: Truist raised its price target to $40 from $30, Oppenheimer to $36 from $32, and Stephens to $34 from $33. On August 10, Barclays upgraded the stock to Overweight and raised its target to $35 from $26, citing faster-than-expected portfolio momentum and share gains.

What Drove JHX Stock Performance Over the Last Quarter

The broader quarterly advance reflects improving confidence in the company's post-AZEK integration and a return to organic fiber-cement growth. After fourth-quarter and full-year fiscal 2026 results were reported on May 19, shares recovered from a mid-May low near $18.51 and climbed steadily through June as the company highlighted fiscal 2027 growth initiatives and synergy targets.

Cost synergies from the AZEK combination have been running ahead of schedule, and management has maintained a commercial revenue-synergy target of a $125 million exit run rate. Free cash flow reached $254 million in the latest quarter, and the company redeemed $400 million of senior unsecured notes, helping reduce net leverage to 2.7 times. The quarterly move, therefore, reflects both short-term earnings momentum and a longer-term deleveraging and integration narrative.

JHX Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, investors are likely to monitor the company's second-quarter fiscal 2027 results and any updates on fiber-cement sell-through versus channel inventory. U.S. housing indicators, including mortgage rates, single-family starts, completions, and repair-and-remodel spending, remain important because management's raised outlook does not assume a housing recovery.

Other factors include the pace of AZEK integration and commercial synergies, distributor transition effects, and progress toward management's leverage targets of roughly 2.4 times by the end of fiscal 2027 and below 2.0 times by the second quarter of fiscal 2028. Cost pressures such as freight inflation and an expected $80 million–$100 million of fiscal 2027 cost headwinds could influence margins. Analyst estimate revisions and valuation sentiment may also shape trading after the stock's sharp advance. From what I see, these elements will be key to sustaining the momentum.

Exploring Tickeron’s Trending AI Robots

I’ve found Tickeron’s Trending AI Robots page helpful for monitoring automated strategies that trade thousands of tickers. It curates top-performing bots across different approaches and timeframes, letting me compare styles and see which ones are gaining attention in shifting markets. This complements my fundamental work on names like JHX. Explore the Trending AI Robots page to see which automated strategies are currently in focus.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: JHX

JHX in +2.81% Uptrend, rising for three consecutive days on August 11, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where JHX advanced for three days, in of 321 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 31, 2026. You may want to consider a long position or call options on JHX as a result. In of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for JHX just turned positive on August 03, 2026. Looking at past instances where JHX's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 226 cases where JHX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JHX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

JHX broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.739) is normal, around the industry mean (2.533). JHX's P/E Ratio (140.273) is considerably higher than the industry average of (31.879). Projected Growth (PEG Ratio) (1.258) is also within normal values, averaging (1.734). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (3.330) is also within normal values, averaging (2.501).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. JHX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JHX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 71, placing this stock worse than average.

Notable companies

The most notable companies in this group are Cemex SAB de CV (NYSE:CX).

Industry description

Many naturally occurring substances, such as clay, rocks, sand, and wood, even twigs and leaves have been used in construction material. Many man-made products are also in use. Vulcan Materials Co., Martin Marietta Materials, Inc. and Owens Corning Inc. are examples of construction material companies in the U.S. Performance of companies that extract or produce construction materials could at times depend on demand for residential and commercial buildings/real estate, and therefore in some cases could feel impacted by economic cycles.

Market Cap

The average market capitalization across the Construction Materials Industry is 12.98B. The market cap for tickers in the group ranges from 323.7K to 65.19B. CRH holds the highest valuation in this group at 65.19B. The lowest valued company is CAPT at 323.7K.

High and low price notable news

The average weekly price growth across all stocks in the Construction Materials Industry was -6%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -12%. JHX experienced the highest price growth at 9%, while RETO experienced the biggest fall at -60%.

Volume

The average weekly volume growth across all stocks in the Construction Materials Industry was 4%. For the same stocks of the Industry, the average monthly volume growth was 80% and the average quarterly volume growth was -0%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 44
P/E Growth Rating: 45
Price Growth Rating: 60
SMR Rating: 61
Profit Risk Rating: 70
Seasonality Score: -63 (-100 ... +100)
View a ticker or compare two or three
JHX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of cement products

Industry ConstructionMaterials

Profile
Details
Industry
Construction Materials
Address
Harcourt Street
Phone
+353 14116924
Employees
5473
Web
https://ir.jameshardie.com.au
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.